Fri.Dec 08, 2023

article thumbnail

FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR’s halo?

Fierce Pharma

Alongside a historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cell | Alongside a historic approval for the first therapy utilizing the Nobel Prize-winning CRISPR/Cas9 gene-editing technology, the FDA has cleared a rival gene replacement therapy, also for sickle cell disease (SCD).

FDA 336
article thumbnail

‘Increasingly Concerned’ Senators Launch Investigation Into Private Equity’s Effect on Healthcare

MedCity News

This week, two bipartisan members of the Senate Budget Committee launched an investigation into private equity and its impact on healthcare. They initiated the probe to get answers about “questionable financial transactions” that could be hurting care quality for patients at hospitals owned by private equity firms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Vertex, CRISPR score landmark FDA approval for sickle cell disease gene therapy Casgevy

Fierce Pharma

Groundbreaking? Game-changing? Transformational? Historic? | Vertex Pharmaceuticals and CRISPR Therapeutics have won an historic FDA approval for their sickle cell disease gene therapy Casgevy. The transformational treatment is a potential cure for the debilitating and life-threatening disease which affects more than 100,000 in the United States, most of them Black.

FDA 319
article thumbnail

How IT Became So Integral in Healthcare in So Little Time

MedCity News

Looking back 20 years, when fewer than 18% of physician practices used electronic health records, few experts would have anticipated how information technology has changed healthcare. Thanks to IT, the volume and types of data generated and the speed at which they can be analyzed are vastly different than decades ago.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Bristol Myers Squibb bids farewell to dealmaking czar Elizabeth Mily

Fierce Pharma

Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. | Three years on, Bristol Myers Squibb is bidding adieu to its top dealmaker. Elizabeth Mily, who replaced BMS’ former M&A czar Paul Biondi back in 2020, is headed for the exit, the company confirmed Friday.

304
304
article thumbnail

Applying the Economy-Wide Lessons of Digital Payments to Clinical Trial Retention

MedCity News

To help keep participants engaged, and on trial, payment and reimbursement systems should offer the same level of flexibility that people have come to expect in every other walk of life.

Biopharma 117

More Trending

article thumbnail

FDA Approves Two Landmark Cell-Based Gene Therapies for Sickle Cell Disease

PharmExec

FDA approval of bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy marks significant milestone in the treatment of sickle cell disease.

FDA 115
article thumbnail

Are Registered Dietitians the Key To Optimizing Weight Loss With GLP-1s?

MedCity News

Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.

article thumbnail

Cambridge researchers redesign future mRNA therapeutics

PharmaTimes

One-third of patients who received Pfizer’s COVID-19 vaccine had unintended immune responses - News - PharmaTimes

Patients 113
article thumbnail

FDA Approves Not One, But Two Sickle Cell Disease Gene Therapies

MedCity News

The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.

FDA 111
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

PharmStars digital health accelerator names fall 2023 grads

pharmaphorum

PharmStars digital health accelerator names fall 2023 grads Phil.

111
111
article thumbnail

StartUPDATES: New developments from healthcare startups

MedCity News

Check out news from FreezeNit, Vascular Perfusion Solutions, Kandu, and BetterYou.

article thumbnail

Africa-led HIV vaccine trial ends in failure

pharmaphorum

Africa-led HIV vaccine trial ends in failure Phil.

110
110
article thumbnail

BioMed X launches call for applications in autoimmune disease research

PharmaTimes

The project will explore the biology of human autoreactive plasma cells - News - PharmaTimes

105
105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn

European Pharmaceutical Review

AbbVie has signed a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline – including antipsychotic emraclidine – for approximately $8.7 billion. Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders.

Safety 105
article thumbnail

A Guide on Determining Stability of Molecular Crystals in Pharmaceutical Drug Development

Pharmaceutical Commerce

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

article thumbnail

AAP Responds To “Flawed” GenAI Arguments

Copyright Clearance Center

AAP responded to tech industry assertions that respect for copyright is an obstacle to their innovation by labeling that as, “nonsense.

98
article thumbnail

Signal: US lays out plan to seize govt-funded drug patents to lower cost

Pharmaceutical Technology

The newly announced plans would allow third parties to manufacture such drugs if manufacturers make them unaffordable.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

MHRA authorises Mounjaro for weight management

European Pharmaceutical Review

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over. Mounjaro is now authorised for adults with a BMI of 30kg/m² or more (obesity), as well as those with a BMI between 27-30kg/m² (overweight) who also have weight-related health problems eg, prediabetes, high blood pressure, high cholesterol, or heart problems.

article thumbnail

AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies

PharmaTech

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

97
article thumbnail

Pfizer’s multiple myeloma treatment secures conditional approval in EU

Pharmaceutical Technology

Pfizer has added the EU to its growing number of markets for its targeted immunotherapy intended for relapsed/refractory multiple myeloma.

article thumbnail

Spyre raises $180m to advance IBD antibody pipeline

pharmaphorum

Spyre raises $180m to advance IBD antibody pipeline Phil.

90
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

The Human Behind the Screen: Why Empathy Matters in your Healthcare IT Strategy

MedCity News

As healthcare IT undergoes continual evolution, the integration of automation and human connection is poised to define the trajectory of IT support. This synergy promises a smooth experience for users and ultimately contributes to enhanced patient care.

article thumbnail

FDA clears two sickle-cell gene therapies, including CRISPR first

pharmaphorum

The US FDA has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.

FDA 87
article thumbnail

The FDA is poised to approve the first CRISPR drug. Here’s what’s next in gene editing.

PharmaVoice

A look at the fast-evolving pipeline for gene editing therapies.

FDA 72
article thumbnail

Regeneron bids to join the BCMA bispecific camp

pharmaphorum

Regeneron bids to join the BCMA bispecific camp Phil.

64
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Addressing Burnout: Why Psychological Safety Matters at Work

Pharmacy Times

Psychological safety substantially contributes to team effectiveness, learning, employee retention, and—most critically—better decisions and better performance.

Safety 64
article thumbnail

Market Trends To Watch in 2024: Q&A With Seth Farbman, Chairman and Co-Founder of VStock Transfer

PharmExec

Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.

article thumbnail

FDA Approves Casgevy, Lyfgenia for the Treatment of Sickle Cell Disease

Pharmacy Times

This FDA approval represents the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

FDA 59
article thumbnail

Embracing the Future: Meeting Doctors and Patients Where They Are Now

PharmExec

Pharma companies must embrace the future to advance commercialization.

Doctors 59
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A